C
3.62
-0.23 (-5.97%)
| Penutupan Terdahulu | 3.85 |
| Jumlah Dagangan | 3,679 |
| Harga / Buku (P/B) | 0.310 |
| Julat 52 Minggu |
| EPS Cair (TTM) | 801.26 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.92% |
| Nisbah Semasa (MRQ) | 4.94 |
| Aliran Tunai Operasi (OCF TTM) | -17.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -12.32 M |
| Pulangan Atas Aset (ROA TTM) | -127.31% |
| Pulangan Atas Ekuiti (ROE TTM) | -477.53% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | CNS Pharmaceuticals, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Nilai 35% | 0.0 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | 0.0 |
| Masa 35% | -3.5 |
| AI Technical info | NA |
| Osilator Teknikal info | -2.5 |
| Purata Bergerak Teknikal info | -5.0 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -22.4% |
| Persetujuan Tonggak | ×1.00 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 0.2 |
| Skor Akhir | -1.48 |
|
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.21% |
| % Dimiliki oleh Institusi | 1.17% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Barrett & Company, Inc. | 30 Sep 2026 | 8 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |